Kiin Bio is a technology company.
Kiin Bio has raised $2.0M across 1 funding round.
Kiin Bio has raised $2.0M in total across 1 funding round.
Kiin Bio has raised $2.0M in total across 1 funding round.
Kiin Bio's investors include btov Partners, Founderful, Join Capital.
Kiin Bio is a 2024-founded London-based technology company developing an AI-native platform for drug discovery. Their core product is a Virtual Scientist Platform that integrates and orchestrates various drug discovery tools—such as lab databases, modeling software, and analysis pipelines—into a unified workflow. This platform uses generative AI agents ("Virtual Scientists") to accelerate research by automating hypothesis generation, experiment planning, and data analysis, aiming to increase R&D output without requiring additional human hires. Kiin Bio serves biotech companies, academic labs, and pharmaceutical R&D teams, addressing inefficiencies caused by fragmented and siloed drug discovery processes. The company has gained early traction through a €1.9 million (approximately $2.2 million) pre-seed funding round led by b2venture and is actively partnering with labs to refine its platform and expand its ecosystem[1][2][3][5].
Kiin Bio was founded in 2024 by CEO Filippo Abbondanza (PhD in bioinformatics, with experience at Lifebit), CDSO Mark Davies (formerly at BenevolentAI), and CTO Bogdan Urse (infrastructure lead at Lifebit). The founders bring a blend of scientific depth, technical expertise, and business acumen, positioning the company at the intersection of biotech and AI. The idea emerged from recognizing the fragmented nature of drug discovery workflows and the need for an integrated AI-driven platform that could unify disparate tools and automate complex R&D tasks. Early pivotal moments include securing oversubscribed pre-seed funding and launching pilot programs with biotech and academic partners to validate and enhance their Virtual Scientist Platform[1][3][4].
Kiin Bio is riding the wave of generative AI adoption in pharmaceutical R&D, a sector projected to generate up to $110 billion annually. The timing is critical as traditional drug discovery is costly, fragmented, and slow, with many isolated tools failing to deliver productivity gains. Kiin Bio’s platform addresses this by creating a cohesive AI-driven infrastructure that can accelerate the journey from scientific idea to life-saving medicine. By enabling vertical integration and automation, Kiin Bio is positioned to influence the broader ecosystem by becoming a foundational technology partner for thousands of drug discovery teams worldwide. This aligns with broader trends toward AI-driven automation and digital transformation in biotech[1][3][4][5].
Kiin Bio’s next steps involve scaling its client base, enhancing AI capabilities, and expanding its marketplace ecosystem. The company aims to evolve from a smart assistant to an operating system for autonomous drug discovery, integrating with lab robots and automating experimental cycles. Future trends shaping their journey include increasing adoption of AI in biotech, demand for integrated platforms, and advances in lab automation. Kiin Bio’s influence is likely to grow as it helps unify fragmented R&D processes, potentially becoming a backbone technology in the pharmaceutical industry’s digital transformation. Their innovative approach and strong team suggest they will remain a key player in the emerging AI-driven drug discovery landscape[1][3][4][5].
Kiin Bio has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $2.0M Seed | btov Partners, Founderful, Join Capital |